Status:
COMPLETED
Calcitonin Gene Related Peptide-Induced Headache in Patients With Familial Hemiplegic Migraine Type 1 and 2.
Lead Sponsor:
Danish Headache Center
Collaborating Sponsors:
EUROHEAD
Conditions:
Familial Hemiplegic Migraine
Eligibility:
All Genders
Phase:
NA
Brief Summary
The aim of the present study is to explore functional consequences of migraine gene mutations on their responses to Calcitonin Gene Related Peptide (CGRP)infusion.
Detailed Description
Calcitonin Gene Related Peptide (CGRP) induces migraine attacks indistinguishable from spontaneous attacks in approximately 50% of migraine sufferers. Treatment of spontaneous migraine attacks with an...
Eligibility Criteria
Inclusion
- Patients: Diagnosis of familial hemiplegic migraine (IHS-classification criteria) caused by mutations in the CACNA1A gene and the ATP1A2 gene.
- Controls: Healthy volunteers
Exclusion
- Controls: No primary headache in their own history 2) Patients and controls:
- A history of cerebrovascular disease and other CNS- disease
- A history of serious somatic and mental disease
- A history suggesting ischaemic heart disease
- A history of hypo- or hypertension
- Daily intake of medication apart from oral contraceptives
- Abuse of alcohol or medicine (opioid analgesics).
- Pregnant or breastfeeding women.
- On the study day:
- No intake of a simple analgesic in the previous 48 hours
- No headache in the previous 48 hours
Key Trial Info
Start Date :
July 1 2006
Trial Type :
INTERVENTIONAL
End Date :
October 1 2006
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT00358839
Start Date
July 1 2006
End Date
October 1 2006
Last Update
November 10 2006
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Danish Headache Center
Glostrup, Copenhagen, Denmark, 2600